Alnylam Pharmaceuticals Inc ALNY:NASDAQ

Last Price$133.10NASDAQ Closing Price as of 3:59PM ET 5/28/20
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change-0.25(0.19%)
Bid (Size)$110.00 (2)
Ask (Size)$142.00 (1)
Day Low / High$132.47 - 136.14
Volume578.6 K
 

View Biotechnology IndustryPeer Comparison as of 05/28/2020

 

Alnylam Pharmaceuticals Inc ( NASDAQ )

Price: $133.10
Change: -0.25 (0.19%)
Volume: 578.6 K
3:59PM ET 5/28/2020
 
 

Exact Sciences Corp ( NASDAQ )

Price: $83.88
Change: +1.77 (2.16%)
Volume: 1.2 M
3:59PM ET 5/28/2020
 
 

Sarepta Therapeutics Inc ( NASDAQ )

Price: $152.98
Change: -4.18 (2.66%)
Volume: 1.4 M
4:00PM ET 5/28/2020
 
 

Biomarin Pharmaceutical Inc ( NASDAQ )

Price: $105.60
Change: -1.10 (1.03%)
Volume: 1.3 M
3:59PM ET 5/28/2020
 
 

Neurocrine Biosciences Inc ( NASDAQ )

Price: $120.24
Change: +1.13 (0.95%)
Volume: 341.4 K
3:59PM ET 5/28/2020
 

Read more news Recent News

--Analyst Actions: UBS Lifts Price Target on Alnylam Pharmaceuticals to $122 From $111, Maintains Neutral Rating
2:31PM ET 5/28/2020 MT Newswires

Price: 135.35, Change: +1.99, Percent Change: +1.50 ...

Alnylam Says FDA Grants Priority Review for Rare Kidney Disorder Drug Lumasiran
11:05AM ET 5/26/2020 MT Newswires

Alnylam Pharmaceuticals (ALNY) said Tuesday that the US Food and Drug Administration has granted priority review for the company's new drug application for...

Alnylam Pharmaceuticals Says Genetic Therapy Improves Symptoms in Neuropathy, Liver Transplant Patients
2:05PM ET 5/22/2020 MT Newswires

Alnylam Pharmaceuticals (ALNY), a genetic therapeutics company, said Friday that patients treated with its patisiran drug candidate showed sustained...

Analyst Actions: RBC Capital Initiates Coverage on Alnylam Pharmaceuticals at Sector Perform With $150 Price Target
8:27AM ET 5/13/2020 MT Newswires

Alnylam Pharmaceuticals (ALNY) has an average rating among analysts of buy, with an average price target of $146. Price: 144.19, Change: +1.76, Percent...

View all Commentary and Analysis

Pandemic Damage And The Vaccine Industry
6:46AM ET 5/26/2020 Seeking Alpha

Alnylam's Positive Data, And Other News: The Good, Bad And Ugly Of Biopharma
3:44AM ET 5/24/2020 Seeking Alpha

Alnylam: The Value Realisation Is Tantalisingly Close
2:24PM ET 5/22/2020 Seeking Alpha

Biotech's Golden Moment As Healthcare Attracts Investors
9:31AM ET 5/12/2020 Seeking Alpha

Company Profile

Business DescriptionAlnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA. View company web site for more details
Address675 West Kendall Street
Cambridge, Massachusetts 02142
Phone+1.617.551.8200
Number of Employees1,065
Recent SEC Filing05/22/20204
Chief Executive Officer & DirectorJohn M. Maraganore
PresidentBarry E. Greene
Chief Operating Officer & Executive Vice PresidentYvonne L. Greenstreet
Chief Financial & Accounting OfficerJeffrey Poulton

Company Highlights

Price Open$135.26
Previous Close$133.35
52 Week Range$65.95 - 151.84
Market Capitalization$15.3 B
Shares Outstanding114.8 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement08/04/2020

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$8.24
Beta vs. S&P 500N/A
Revenue$74.9 M
Net Profit Margin-310.01%
Return on Equity-57.63%

Analyst Ratings as of 05/11/2020

Buy
14
Overweight
1
Hold
6
Underweight
0
Sell
1
Consensus RecommendationConsensus Icon
Powered by Factset